Company Description
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally.
It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures.
The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and chronic wounds.
It also markets PACE systems that use acoustic pressure shockwaves generated by pulsed acoustic cellular expression technology to converge at selected areas for wound and orthopedic applications under the dermaPACE, Profile, and orthoPACE brand names.
The company was founded in 2004 and is headquartered in Eden Prairie, Minnesota.
| Country | United States |
| Founded | 2004 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Morgan Frank |
Contact Details
Address: 11495 Valley View Road Eden Prairie, Minnesota 55344 United States | |
| Phone | 952 656 1029 |
| Website | sanuwave.com |
Stock Details
| Ticker Symbol | SNWV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001417663 |
| CUSIP Number | 80303D107 |
| ISIN Number | US80303D1072 |
| Employer ID | 20-1176000 |
Key Executives
| Name | Position |
|---|---|
| Morgan C. Frank | Chief Executive Officer and Chairman |
| Andrew Walko | President |
| Peter Sorensen | Chief Financial Officer and Secretary |
| Peter Stegagno | Chief Operating Officer |
| Timothy Wern | Executive Vice President of Sales - U.S. Wound |
| Dustin Libby | Executive Vice President of Commercial Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2025 | 8-K | Current Report |
| Aug 7, 2025 | 10-Q | Quarterly Report |
| Jul 31, 2025 | 8-K | Current Report |
| Jul 29, 2025 | SCHEDULE 13G | Filing |
| Jul 14, 2025 | 8-K | Current Report |
| Jul 10, 2025 | ARS | Filing |
| Jul 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 10, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 26, 2025 | 8-K | Current Report |
| Jun 25, 2025 | 144 | Filing |